To offer cross-protection against diverse influenza virus variants, nanoparticle vaccines can produce pivotal cellular and mucosal immune responses that enhance vaccine efficacy and broaden protection, according to a study by researchers in the Institute for Biomedical Sciences at Georgia State University.
Past and present FDA adcomm members weigh in on potential reforms
A majority of former and current FDA advisory committee members surveyed in July supported remote participation in meetings and better communication, as the FDA considers
August 14, 2024